Maria Pilar Laguna
Research Subjects
Research Interests
Maria Pilar Laguna has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
Jean J.M.C.H. de la Rosette
Department of Urology, AMC University Hospital , Amsterdam, The Netherlands
6 shared publicationsH. Wijkstra
Servicio de Urología. Hospital AMC. Ámsterdam, Holanda
5 shared publicationsHessel Wijkstra
Department of Urology, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
5 shared publications- Jean J. M. C. H. de la Rosette
Department of Urology, Academic Medical Center University Hospital, Amsterdam, The Netherlands
5 shared publications J J De La Rosette
4 shared publications- Kurdo Barwari
Department of Urology, AMC University Hospital, University of Amsterdam, Amsterdam, The Netherlands
4 shared publications
Latest Publications
- 17 August 2017
- Published by Springer Nature
- p. 75-86
Laparoscopic and Percutaneous Cryoablation of Small Renal Masses
- 17 August 2017
- Published by Springer Nature
- p. 75-86
Laparoscopic and Percutaneous Cryoablation of Small Renal Masses
- 1 December 2016
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 36, 533-540
Cryoablation of small kidney tumors
Cryoablation (CA) has been broadly used mostly in the treatment of small renal masses (SRMs). The present review aims to define the current role of CA in the treatment of SRMs by assessing clinical indications and outcomes. A comprehensive review on patient selection, procedural details, perioperative complications, and short/long-term oncological and functional outcomes was conducted. For each section, a take-home message was formulated with level of evidence (LoE) according to Cochrane collaboration. Age and comorbidity drive the choice of ablation in SRMs, although hospital setting also influences the decision. Technically in adequate CA or first post-CA control occurs in 3-5% of laparoscopic cryoablation (LCA) or percutaneous cryoablation (PCA) series. Meta-analysis does not evidence differences in the rate of residual tumor per person-year between the approaches (0.033 LCA vs. 0.046 PCA, p = 0.25). Perioperative complications (8-25%) are erratically reported. LCA has significantly lower likelihood of complications than minimally invasive partial nephrectomy (MIPN). Systematic reviews indicate 30-month local tumor progression rate of 8.5% for LCA in renal cell carcinoma but low metastatic progression (1-4.4%). Few LCA long-term follow-up series (mean/media 48-98 months) report recurrence-free survival (RFS) and cancer-specific survival (CSS) ranges of 80-100%. For PCA, Kaplan-Meier local disease-free survival (DFS) of 95.6% at 3-5 years [32] and 5-year overall survival and local RFS of 86.3% were reported. The decrease in renal function after CA is minimal, and the only risk factor associated is the basal estimated glomerular filtration rate (eGFR). LoE 3a/b confirms lower CA perioperative complication rate and higher local progression rate than those for MIPN. CA preserves postoperative renal functional, without any evidence of differences in mid-/long-term follow-up compared to nephron sparing surgery.
- 1 December 2016
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 36, 533-540
Cryoablation of small kidney tumors
Cryoablation (CA) has been broadly used mostly in the treatment of small renal masses (SRMs). The present review aims to define the current role of CA in the treatment of SRMs by assessing clinical indications and outcomes. A comprehensive review on patient selection, procedural details, perioperative complications, and short/long-term oncological and functional outcomes was conducted. For each section, a take-home message was formulated with level of evidence (LoE) according to Cochrane collaboration. Age and comorbidity drive the choice of ablation in SRMs, although hospital setting also influences the decision. Technically in adequate CA or first post-CA control occurs in 3-5% of laparoscopic cryoablation (LCA) or percutaneous cryoablation (PCA) series. Meta-analysis does not evidence differences in the rate of residual tumor per person-year between the approaches (0.033 LCA vs. 0.046 PCA, p = 0.25). Perioperative complications (8-25%) are erratically reported. LCA has significantly lower likelihood of complications than minimally invasive partial nephrectomy (MIPN). Systematic reviews indicate 30-month local tumor progression rate of 8.5% for LCA in renal cell carcinoma but low metastatic progression (1-4.4%). Few LCA long-term follow-up series (mean/media 48-98 months) report recurrence-free survival (RFS) and cancer-specific survival (CSS) ranges of 80-100%. For PCA, Kaplan-Meier local disease-free survival (DFS) of 95.6% at 3-5 years [32] and 5-year overall survival and local RFS of 86.3% were reported. The decrease in renal function after CA is minimal, and the only risk factor associated is the basal estimated glomerular filtration rate (eGFR). LoE 3a/b confirms lower CA perioperative complication rate and higher local progression rate than those for MIPN. CA preserves postoperative renal functional, without any evidence of differences in mid-/long-term follow-up compared to nephron sparing surgery.
- 1 January 2016
- Published by SAGE Publications in Journal of Endourology
- Vol. 30 (1) , 128-134
Preoperative Decision Making for Nephron-Sparing Procedure in the Renal Mass: Time for Using Standard Tools?
Objective: To determine if the application of using standard tools on tumor complexity and comorbidity indexes may replace the traditional choice of nephron-sparing procedure (NSP) based on clinical maximal tumor diameter (cMTD), age, and comorbidity. Patients and Methods: Anatomic complexity scores (PADUA and RENAL) and Charlson comorbidity index (CCI) and CCI age-adjusted (CACI) were applied to 261 cases of either nephron-sparing surgery (NSS) or cryoablation (CA). Patient- and tumor-related preoperative variables, PADUA, RENAL, CCI, and CACI, were evaluated for their association and as treatment predictors in uni- and multivariate regression analysis. Discriminative ability of each of the models generated was compared for their receiver operating curve area under the curve (AUC). Survival analysis was performed using log rank tests. Results: In total, 124 cases underwent partial nephrectomy and 137 cases CA. cMTD, RENAL, PADUA, age, and CACI were independently associated with the choice of NSS. Five models integrating a combination of age, cMTD, CACI, PADUA, and RENAL (scores and complexity groups) showed an AUC >0.72 to predict the odds of receiving NSS. The discriminative ability of these five models was not statistically significantly different. Conclusions: cMTD, RENAL, PADUA, age, and CACI are preoperative variables independently associated with the choice of NSP. Models incorporating tools on tumor anatomic complexity and CACI may replace the decision-making in the type of NSP based on cMTD and age. The use of these models can be of value for future standardization and comparison.
- 1 January 2016
- Published by SAGE Publications in Journal of Endourology
- Vol. 30 (1) , 128-134
Preoperative Decision Making for Nephron-Sparing Procedure in the Renal Mass: Time for Using Standard Tools?
Objective: To determine if the application of using standard tools on tumor complexity and comorbidity indexes may replace the traditional choice of nephron-sparing procedure (NSP) based on clinical maximal tumor diameter (cMTD), age, and comorbidity. Patients and Methods: Anatomic complexity scores (PADUA and RENAL) and Charlson comorbidity index (CCI) and CCI age-adjusted (CACI) were applied to 261 cases of either nephron-sparing surgery (NSS) or cryoablation (CA). Patient- and tumor-related preoperative variables, PADUA, RENAL, CCI, and CACI, were evaluated for their association and as treatment predictors in uni- and multivariate regression analysis. Discriminative ability of each of the models generated was compared for their receiver operating curve area under the curve (AUC). Survival analysis was performed using log rank tests. Results: In total, 124 cases underwent partial nephrectomy and 137 cases CA. cMTD, RENAL, PADUA, age, and CACI were independently associated with the choice of NSS. Five models integrating a combination of age, cMTD, CACI, PADUA, and RENAL (scores and complexity groups) showed an AUC >0.72 to predict the odds of receiving NSS. The discriminative ability of these five models was not statistically significantly different. Conclusions: cMTD, RENAL, PADUA, age, and CACI are preoperative variables independently associated with the choice of NSP. Models incorporating tools on tumor anatomic complexity and CACI may replace the decision-making in the type of NSP based on cMTD and age. The use of these models can be of value for future standardization and comparison.
- 1 November 2015
- Published by Elsevier in European Urology
- Vol. 68 (5) , 908
Re: Subcentimeter Pulmonary Nodules Are Not Associated with Disease Progression in Patients with Renal Cell Carcinoma
- 1 November 2015
- Published by Elsevier in European Urology
- Vol. 68 (5) , 908
Re: Subcentimeter Pulmonary Nodules Are Not Associated with Disease Progression in Patients with Renal Cell Carcinoma
- 25 October 2015
- Published by Wiley in BJU International
- Vol. 117 (6) , 914-922
Prediction of renal mass aggressiveness using clinical and radiographic features: a global, multicentre prospective study
Objective: To examine the ability of preoperative clinical characteristics to predict histological features of renal masses ( RM s). Patients and Methods: Data from consecutive patients with clinical stage I RM s treated surgically between 2010 and 2011 in the Clinical Research Office of Endourology Society ( CROES ) Renal Mass Registry were collected. Based on surgical histology, tumours were categorised as benign, low‐ or high‐aggressiveness cancer. Multivariate logistic regression was used to estimate the probability of the histological group by clinical and radiographic features in the entire cohort and a subcohort of cT 1a tumours. The performance of the models was studied by calibration, Nagelkerke's R 2 , and discrimination (area under the receiver operating characteristic curve). Results: The study cohort included 2 224 patients with a clinical stage I RM , of which 1 367 (61%) were cT 1a. Benign lesions were found in 369 (16.6%), low‐aggressiveness tumours in 1 156 (52%) and high‐aggressiveness tumours in 699 (31.4%). Male gender, smoking history, increased tumour size, and lower exophytic rate were associated with malignancy and high‐aggressiveness features (all P < 0.05). Models developed based on these characteristics had the ability to discriminate benign from malignant (bootstrap corrected c ‐index of 0.64) and high‐aggressiveness tumours from benign and low‐aggressiveness tumours (bootstrap corrected c ‐index of 0.66). Similar results were achieved in the cT 1a subgroup. The c ‐index of tumour diameter as a single predictor of malignancy and high‐aggressiveness tumours in the entire cohort was 0.6 and 0.63, respectively. Conclusion: Although older age, male gender, smoking history, increased tumour diameter, and reduced exophytic rate are associated with malignancy and high aggressiveness of clinical stage I RM s, models incorporating these characteristics have modest discriminating power, being only slightly better than the predictive ability of tumour size alone.
- 25 October 2015
- Published by Wiley in BJU International
- Vol. 117 (6) , 914-922
Prediction of renal mass aggressiveness using clinical and radiographic features: a global, multicentre prospective study
Objective: To examine the ability of preoperative clinical characteristics to predict histological features of renal masses ( RM s). Patients and Methods: Data from consecutive patients with clinical stage I RM s treated surgically between 2010 and 2011 in the Clinical Research Office of Endourology Society ( CROES ) Renal Mass Registry were collected. Based on surgical histology, tumours were categorised as benign, low‐ or high‐aggressiveness cancer. Multivariate logistic regression was used to estimate the probability of the histological group by clinical and radiographic features in the entire cohort and a subcohort of cT 1a tumours. The performance of the models was studied by calibration, Nagelkerke's R 2 , and discrimination (area under the receiver operating characteristic curve). Results: The study cohort included 2 224 patients with a clinical stage I RM , of which 1 367 (61%) were cT 1a. Benign lesions were found in 369 (16.6%), low‐aggressiveness tumours in 1 156 (52%) and high‐aggressiveness tumours in 699 (31.4%). Male gender, smoking history, increased tumour size, and lower exophytic rate were associated with malignancy and high‐aggressiveness features (all P < 0.05). Models developed based on these characteristics had the ability to discriminate benign from malignant (bootstrap corrected c ‐index of 0.64) and high‐aggressiveness tumours from benign and low‐aggressiveness tumours (bootstrap corrected c ‐index of 0.66). Similar results were achieved in the cT 1a subgroup. The c ‐index of tumour diameter as a single predictor of malignancy and high‐aggressiveness tumours in the entire cohort was 0.6 and 0.63, respectively. Conclusion: Although older age, male gender, smoking history, increased tumour diameter, and reduced exophytic rate are associated with malignancy and high aggressiveness of clinical stage I RM s, models incorporating these characteristics have modest discriminating power, being only slightly better than the predictive ability of tumour size alone.
- 1 April 2015
- Vol. 68 (3) , 307-315
Advances in ultrasound techniques for the diagnosis and staging of prostate cancer. Elastography, Doppler ultrasound, ultrasound contrast media, ultrasound quantification media and MRI fusion
OBJECTIVES: Transrectal ultrasound-guided prostate biopsy remains the gold standard in the diagnosis of prostate cancer. Various Ultrasound modalities have been proposed to increase the cancer detection rate. Our purpose is to evaluate each of these methods, and to present its current literature and clinical utility. METHOD: A non structured review of the current literature was conducted over these different various ultrasound modalities used during the transrectal ultrasound-guided prostate biopsied in the diagnosis of prostate cancer. RESULTS: The data investigation of the various modalities associated sonographic features exhibits great heterogeneity and highly variable results. Some new techniques sampling present promising results with high sensitivity and specificity, thus increasing the diagnostic yield of transrectal biopsy It seems that elastography shows encouraging figures, especially given the recent introduction of the "shearvawe" elastography that decreases the user-dependent factor. CONCLUSIONS: The ultrasound-guided prostate biopsy has an acceptable sensitivity in the diagnosis of prostate cancer, but its specificity is still low. Various modalities associated with ultrasound are available in clinical practice in order to increase cancer detection rate. Although some promising data have been published for some of the modalities, we believe the combination of these includes validated ultrasound guided biopsy protocols to accurately target and diagnose prostate cancer.
- 1 April 2015
- Vol. 68 (3) , 307-315
Advances in ultrasound techniques for the diagnosis and staging of prostate cancer. Elastography, Doppler ultrasound, ultrasound contrast media, ultrasound quantification media and MRI fusion
OBJECTIVES: Transrectal ultrasound-guided prostate biopsy remains the gold standard in the diagnosis of prostate cancer. Various Ultrasound modalities have been proposed to increase the cancer detection rate. Our purpose is to evaluate each of these methods, and to present its current literature and clinical utility. METHOD: A non structured review of the current literature was conducted over these different various ultrasound modalities used during the transrectal ultrasound-guided prostate biopsied in the diagnosis of prostate cancer. RESULTS: The data investigation of the various modalities associated sonographic features exhibits great heterogeneity and highly variable results. Some new techniques sampling present promising results with high sensitivity and specificity, thus increasing the diagnostic yield of transrectal biopsy It seems that elastography shows encouraging figures, especially given the recent introduction of the "shearvawe" elastography that decreases the user-dependent factor. CONCLUSIONS: The ultrasound-guided prostate biopsy has an acceptable sensitivity in the diagnosis of prostate cancer, but its specificity is still low. Various modalities associated with ultrasound are available in clinical practice in order to increase cancer detection rate. Although some promising data have been published for some of the modalities, we believe the combination of these includes validated ultrasound guided biopsy protocols to accurately target and diagnose prostate cancer.
- Open Access
- 1 January 2015
- Published by Polskie Towarzystwo Urologiczne in Central European Journal of Urology
- Vol. 68 (2) , 137-8
What matters when selecting candidates for renal ablation: tumor size or the patient’s condition?
- 1 January 2015
- Published by Polskie Towarzystwo Urologiczne in Central European Journal of Urology
- Vol. 68 (2) , 137-8
Open AccessWhat matters when selecting candidates for renal ablation: tumor size or the patient’s condition?
- 1 July 2014
- Vol. 67 (6) , 521-8
[Diagnosis of upper urinary tract tumors. A pending challenge].
Early diagnosis of upper urinary tract tumors is not easy. The development of endoscopic equipment has expanded the group of patients candidates for minimally invasive treatment. Only by providing accurate tumor staging and grading can clinicians decide which patients should be offered conservative therapies. We need diagnostic methods that allow us to make an early and accurate diagnosis for these lesions, as well as safe follow-up. Our proposal is to present a review of the most used diagnostic method, their features, and future diagnostic tools. The diagnostic arsenal requires further improvement. Only through accurate diagnosis, we will be able to safely provide conservative treatment. Developing new diagnostic techniques seem to move us closer to this goal even more. We propose a working algorithm on the management of these lesions.
- 1 July 2014
- Vol. 67 (6) , 521-8
[Diagnosis of upper urinary tract tumors. A pending challenge].
Early diagnosis of upper urinary tract tumors is not easy. The development of endoscopic equipment has expanded the group of patients candidates for minimally invasive treatment. Only by providing accurate tumor staging and grading can clinicians decide which patients should be offered conservative therapies. We need diagnostic methods that allow us to make an early and accurate diagnosis for these lesions, as well as safe follow-up. Our proposal is to present a review of the most used diagnostic method, their features, and future diagnostic tools. The diagnostic arsenal requires further improvement. Only through accurate diagnosis, we will be able to safely provide conservative treatment. Developing new diagnostic techniques seem to move us closer to this goal even more. We propose a working algorithm on the management of these lesions.
- 31 May 2014
- Published by Elsevier in European Urology
- Vol. 65 (5) , 965-966
Are We Ready for Molecular Imaging–Guided Surgery?
- 31 May 2014
- Published by Elsevier in European Urology
- Vol. 65 (5) , 965-966
Are We Ready for Molecular Imaging–Guided Surgery?
- 1 April 2014
- Published by Elsevier in European Urology Supplements
- Vol. 13 (1) , e97
97 Intermediate term oncologic outcomes of renal cryoablation: An international multi-institution analysis
- 1 April 2014
- Published by Elsevier in European Urology Supplements
- Vol. 13 (1) , e97
97 Intermediate term oncologic outcomes of renal cryoablation: An international multi-institution analysis